Elacestrant has become the first oral SERD to generate positive topline results in a pivotal study as a monotherapy versus standard of care for ER+/HER2- advanced or metastatic breast cancer.
While a number of oral SERD (selective estrogen receptor degrader) breast cancer drugs are moving closer to the market, Menarini Groupand partner Radius Health, Inc. have moved ahead of the pack with promising late-stage data for elacestrant.
The partners have announced positive topline progression-free survival (PFS) results from the Phase III EMERALD trial for elacestrant, their SERD for advanced or metastatic treatment-experienced ER+/HER2- breast cancer
The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.
Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.
Shares are hit as German conglomerate lowers revenue forecast.
